Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter–22q11.2 by Hulsebos, T J M et al.
Ependymomas are glial neoplasms developing from ependymal
cells that line the cerebral ventricles and the central canal of the
spinal cord. They are most commonly seen in children and adoles-
cents in which they account for about 10% of all brain tumours
(Russell and Rubinstein, 1989). Only a limited number of genetic
changes have been reported for this type of tumou r. Loss of
heterozygosity for chromosome 22 (LOH 22) is a rather frequent
event (about 30% of cases) in adult ependymomas but is infre-
quent in pediatric ependymomas (Bijlsma et al, 1995;  Von Haken
et al, 1996). Neurofibromatosis type 2 (NF2) patients are at
increased risk of developing a spinal ependymoma (Martuza et al,
1988). Indeed, mutations in th e NF2gene on chromosome 22 have
been found in sporadic spinal cord ependymomas, but not in
sporadic intracranial ependymomas (Rubio et al, 1994; Ng et al,
1995; Slavc et al, 1995; Birch et al, 1996;  Von Haken et al, 1996).
TP53gene mutations are rare in sporadic intracranial as well as
spinal ependymomas ( Von Haken et al, 1996; Nozaki et al, 1998).
In one study, frequent LOH was found for the region on chromo-
some arm 17p distal to th e TP53gene (Von Haken et al, 1996). No
other regions or genes have been identified as being frequently
involved in ependymoma tumorigenesis (Bijlsma et al, 1995; for
review, see Hamilton and Pollack, 1997).
A consistent cytogenetic aberration in a tumour may point to the
presence of a gene that is involved in the generation of that
tumour. In this respect,  Weremowicz et al (1992) found in the
anaplastic ependymoma of a 5-yea r-old boy loss of one copy of
chromosome 22 and a balanced 1/22 translocation with the break-
point at 22q13.3 in the retained homologue. This suggests the
presence of an ependymoma tumour suppressor gene in the telo-
meric part of chromosome 22. On the other hand, a patient with a
malignant ependymoma at age 5 has been reported to carry a
balanced constitutional t(1;22) (p22; q 11.2) with the chromosome
22 breakpoint between ARVCFand D22S264in the centromeric
part of chromosome arm 22q (Park et al, 1996; Rhodes et al,
1997). This may indicate that an ependymoma-causative gene is
located at that position.
Clustering of ependymomas has been noted in some families,
suggesting inheritance of a genetic susceptibility to this type of
tumour. Honan et al (1987) reported on a family of  11 siblings, of
when five developed brain tumours: three had a subependymoma,
one an ependymoma and one a brain tumour of unknown
pathology. In another famil y, two sisters and their mothe r’s male
cousin all developed an ependymoma (Savard and Gilchrist,
1989). One of the sisters had monosomy 22 in the tumou r. Ryken
et al (1994) presented in their study a father and son, who both
developed a subependymoma. Finally, we reported previously on a
family with four male cousins, whose fathers were brothers, with
verified anaplastic ependymoma in three cases and evidence of
ependymoma in the fourth case (Nijssen et al, 1994). Monosomy
22, but no mutation in th e NF2gene, was found in the ependy-
moma of one of the patients.
Taken together, the available data suggest that an ependymma-
related tumour suppressor gene, of which the mutated form
segregates in ependymoma families and which is inactivated by
loss in the tumour, might be present on chromosome 22. To
localize that gene, we performed a segregation analysis, using a set
of markers that covers the whole chromosome 22, in the ependy-
moma family that was presented previously (Nijssen et al, 1994).
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Summar yEpendymomas are glial tumours of the brain and spinal cord. The most frequent genetic change in sporadic ependymoma is
monosomy 22, suggesting the presence of an ependymoma tumour suppressor gene on that chromosome. Clustering of ependymomas has
been reported to occur in some families. From an earlier study in a family in which four cousins developed an ependymoma, we concluded
that an ependymoma-susceptibility gene, which is not the NF2 gene in 22q12, might be located on chromosome 22. To localize that gene, we
performed a segregation analysis with chromosome 22 markers in this family. This analysis revealed that the susceptibility gene may be
located proximal to marker D22S941 in 22pter–22q11.2. Comparative genomic hybridization showed that monosomy 22 was the sole
detectable genetic aberration in the tumour of one of the patients. Loss of heterozygosity studies in that tumour revealed that, in accordance
to Knudson’s two-hit theory of tumorigenesis, the lost chromosome 22 originated from the parent presumed to have contributed the wild-type
allele of the susceptibility gene. Thus, our segregation and tumour studies collectively indicate that an ependymoma tumour suppressor gene
may be present in region 22pter–22q11.2. ©1999 Cancer Research Campaign
Keywords :ependymoma; familial clustering; tumour suppressor gene; chromosome 22
1150
British Journal of Cance r(1999) 81(7), 1150–1154
©1999 Cancer Research Campaign
Article no. bjoc.1999.0822
Received 12 January 1999
Revised 19 April 1999
Accepted 22 April 1999
Correspondence to : TJM HulsebosIn addition, we analysed the ependymomas of two patients in this
family for loss of chromosome 22 markers. From these analyses
we conclude that an ependymoma tumour suppressor gene may be
present in region 22pter-22q11.2.
MATERIALS AND METHODS
Family study and clinical data
The pedigree of the family is shown in Figure 1. The clinical data
for the family members have been presented previously (Nijssen
et al, 1994). In short, no signs of neurofibromatosis were present
in this family. Individuals III-1, III-3 and III-4 developed a
histopathologically proven intracranial anaplastic ependymoma at
young age (< 5 years). Computerized tomography (CT) scanning
showed a large tumour in the fourth ventricle of patient III-2 at
6 months of age, which was not evident at 3 days after birth.
Histopathological data were not available for this tumour. CT and
magnetic resonance imaging (MRI) showed in patient III-4 at the
age of 8 months an infratentorial tumour, although cerebral CT
was normal at the age of 2 months. Since the earlier CT scans of
two patients showed no significant abnormalities, we think that the
ependymomas were anaplastic from the beginning. Cerebral MRI
of individual II-3 was normal.
Molecular genetics and cytogenetics
Genomic DNA was extracted from blood leucocytes of the family
members and the frozen tumour of patient III-4 as described previ-
ously (Bijlsma et al, 1995). For patient III-1, only formalin-fixed
and paraffin-embedded tumour material was available from which
genomic DNA was isolated according to Speicher et al (1995).
Tumour and normal tissue of patient III-3 was not available.
Comparative genomic hybridization (CGH) for the tumour of
patient III-4 was performed as described (Hermsen et al, 1997).
For microsatellite analysis, primer sequences and polymerase
chain reaction (PCR) conditions were taken from the relevant data-
bases by accession through the Internet. The order of markers on
chromosome 22 used in this study was deduced from published
maps (Collins et al, 1995; Dib et al, 1996). The known cytogenetic
localizations of markers were taken from the Genome Database
and are shown in Figure 2. PCR was performed essentially as
described in Bijlsma et al (1995). LOH in the tumours was deter-
mined by visual inspection of autoradiographs. Due to consider-
able degradation of the DNA extracted from the tumour of patient
III-1, only PCRs generating products smaller than about 150 bp
could be executed using this DNA as template.
RESULTS
Interphase fluorescence in situ hybridization analysis on selected
chromosomes in the tumour of patient III-4 suggested in our
previous study monosomy 22 and normal copy numbers for chro-
mosomes 1, 6, 7, 10, 11, 15, 17, 18, X and Y (Nijssen et al, 1994).
To confirm and extend these observations, we performed CGH
analysis of this tumour. The CGH profile for each chromosome is
shown in Figure 3. Apart from monosomy 22, no other tumour-
related chromosomal changes are present, suggesting that loss of
one copy of chromosome 22 is the sole genetic aberration in this
tumour.
According to Knudson’s two-hit model of tumorigenesis, as
adapted by Cavenee et al (1983), loss of chromosome 22 repre-
sents the second hit, i.e. loss of the wild-type allele of the
presumed tumour suppressor gene. To map the first hit, i.e. the
inactivated allele that segregates in the family, we performed a
genetic analysis of the family members using microsatellite
markers at loci that cover the whole chromosome 22. The results
are summarized in Figure 1. As an example, the genotyping of the
family members for marker D22S427 is shown in Figure 4A.
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Figure 1 Genotype analysis of the family using markers at loci on
chromosome 22. T denotes marker alleles retained in the tumour. Grey
symbols represent patients with ependymoma. To follow their segregation in
the family, the grandparental chromosomes are indicated by differently
coloured bars. Haplotypes for each chromosome were constructed by
assuming minimal numbers of recombinations. The most probable
haplotypes for the grandpaternal chromosomes were inferred from those of
children and spouse. Genotypes for marker D22S446 suggest absence of
one allele (indicated by 0) in the constitutional DNA of individuals I-2 and II-3.
Since individual I-2 is homozygous for D22S941, D22S311, and D22S1163
the recombination events, evident in the constitutional DNA of II-3, could also
have taken place in the region defined by these markers. The segment that is
shared by patients III-1 and III-4 is limited to the region defined by markers
D22S420 and D22S427 in the centromeric part of chromosome arm 22q
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TTHaplotypes for the various chromosomes 22 were constructed by
assuming minimal numbers of recombinations. The two affected
individuals III-1 and III-4 only share the segment of chromosome
22 that is defined by alleles 3 and 1 of markers D22S420 and
D22S427 respectively. These alleles originate from their grand-
mother (I-2).
We analysed the tumours of patients III-1 and III-4 for LOH of
the chromosome 22 markers that were used in the segregation
analysis. Every informative marker displayed LOH in the tumour
of patient III-4 and the lost allele was for each marker of maternal
origin (Figures 1 and 4). Unfortunately, because of heavily
degraded DNA, the LOH status of only three markers could be
successfully determined in the tumour of patient III-1. All three
markers displayed LOH in the tumour, suggesting that at least the
central and telomeric part of chromosome 22 are also lost in that
tumour. The lost alleles originate from the mother of the patient. As
shown in Figure 4B, the retained allele of marker D22S1176, which
is in the NF2 gene region in 22q12 (Figure 2), is different in the two
tumours and both alleles originate from the grandfather (I-1).
DISCUSSION
If one assumes that in the family studied here the histopatho-
logically verified presence of an ependymoma in three of the four
cousins is not merely a coincidence but the consequence of the
inheritance of a mutated susceptibility gene for that tumour, then
the region 22pter-22q11.2 proximal to D22S941 and including
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Figure 2 Linear order and cytogenetic localization of the chromosome 22
markers used in this study. The positions of ARVCF, D22S264, and NF2,
which are discussed in the text, are indicated
Figure 3 CGH analysis of the tumour of patient III-4. The highly polymorphic centromeric and heterochromatic regions are excluded from CGH analysis
because of technical reasons. The figure beneath each profile indicates number of chromosomes analysed to obtain the average profile shown. Normal female
DNA was used as reference DNA. Since the tumour DNA was from a male patient, the profile for the X-chromosome shows apparent loss of one copy in the
tumour. Apart from this, the sole aberration in the tumour is loss of one copy of chromosome 22D22S420 and D22S427 is the most likely location of that gene.
This segment is shared by patients III-1 and III-4, and is inherited
from their grandmother. All other chromosome 22 segments in the
constitutional DNA of these patients are from different chromo-
somes, thereby excluding one origin. In accordance with the
tumour suppressor gene model, the maternal chromosome 22 copy,
carrying the wild-type allele, is lost and the grandmaternal chro-
mosome 22 segment, with the presumed inactivated allele, is
retained in the tumour of patient III-4 (Figure 1). This is exempli-
fied in Figure 4A by loss in the tumour of the maternal allele 5 of
marker D22S427 in the commonly inherited region. In addition, in
case of marker D22S1176, different grandpaternal alleles are
retained in the tumours of patients III-1 and III-4, strongly
suggesting that the closely linked NF2 gene copies also are of
different origin (Figure 4B). This excludes the NF2 gene as the
common susceptibility factor, which is in accordance with our
earlier failure to find a mutation in the NF2 gene in the tumour of
patient III-4 (Nijssen et al, 1994).
The most probable location of the ependymoma-susceptibility
gene is proximal to D22S941 (Figure 1). The chromosome 22
breakpoint of the constitutional t(1;22) (p22;q11.2) in the young
patient with a malignant ependymoma has been mapped between
ARVCF and D22S264 (Rhodes et al, 1997). Considering the order
cen — D22S941 — ARVCF — D22S264 — D22S311 — tel
(Sirotkin et al, 1997), this would indicate that two different genes
are implicated in ependymoma tumorigenesis. Since the precise
physical distances in the region under study are not known yet, the
presence of a very large gene that is inactivated by mutation in our
family and by translocation in the sporadic tumour cannot be
excluded at the moment. Alternatively, as suggested by Rhodes et
al (1997), it is possible that the translocation in their patient causes
the activation of the oncogene, rather than the inactivation of a
tumour suppressor gene, which might be located on chromosome 1
and not on chromosome 22.
It is clear from the absence of affected individuals in genera-
tions I and II that the development of ependymomas in generation
III in the studied family cannot simply be explained by the
mendelian inheritance of a single ependymoma-susceptibility
gene. Absence of disease in earlier generations has also been docu-
mented for other (sub)ependymoma families (Honan et al, 1987;
Savard and Gilchrist, 1989). These family data suggest multifacto-
rial inheritance in which ependymoma development is determined
by two or more loci. The one on chromosome 22 contributes
significantly to the disease phenotype and both copies of that gene
must be inactivated for tumour formation to occur.
The distal boundary of the ependymoma-susceptibility gene
region is defined by the recombination event between D22S427
and D22S941 in individual II-3, as detected in the constitutional
DNA of III-4 (Figure 1). Both markers are within the centromeric
region of chromosome arm 22q that includes the Cat Eye and
DiGeorge Syndrome Critical Regions. The complete nucleotide
sequence of the latter regions is currently being determined (B Roe
et al, personal communication). This sequencing effort will
certainly reveal many new candidate genes, which will be tested
for their involvement in ependymoma tumorigenesis.
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Figure 4 Autoradiographs showing the genotype analysis of family
members and the LOH analysis of the tumour of patient III-4 for marker
D22S427 (A) and the LOH analysis of the tumours of patients III-1 and III-4
for marker D22S1176 (B). N, normal DNA; T, tumour DNA. Deduced
genotypes are shown in Figure 1. LOH analyses display loss of allele 5 of
marker D22S427 in the tumour of patient III-4 and loss of alleles 1 and 4 of
marker D22S1176 in the tumour of patients III-1 and III-4 respectively.1154 TJM Hulsebos et al
British Journal of Cancer (1999) 81(7), 1150–1154 © 1999 Cancer Research Campaign
Nijssen PCG, Lekanne Deprez RH, Tijssen CC, Hagemeijer A, Arnoldus EPJ,
Teepen JLJM, Holl R and Niermeyer MF (1994) Familial anaplastic
ependymoma: evidence of loss of chromosome 22 in tumour cells. J Neurol
Neusosurg Psychiatry 57: 1245–1248
Park JP, Chaffee S, Noll WW and Rhodes CH (1996) Constitutional de novo
t (1;22) (p22; q11.2) and ependymoma. Cancer Genet Cytogenet 86: 150–152
Rhodes CH, Call KM, Budarf ML, Barnoski BL, Bell CJ, Emanuel BS, Bigner SH,
Park JP and Mohandas TK (1997) Molecular studies of an ependymoma-
associated constitutional t (1; 22) (p22; q11.2). Cytogenet Cell Genet 78:
247–252
Rubio M-P, Correa KM, Ramesh V, MacCollin MM, Jacoby LB, Von Deimling A,
Gusella JF and Louis DN (1994) Analysis of the neurofibromatosis 2 gene in
human ependymomas and astrocytomas. Cancer Res 54: 45–47
Russell DS and Rubinstein LJ (1989) Tumours of the ependymoma group. In:
Pathology of Tumours of the Nervous System, 5th edn, pp. 187–219. Edward
Arnold: London
Ryken TC, Robinson RA and VanGilder JC (1994) Familial occurrence of
subependymoma. Report of two cases. J Neurosurg 80: 1108–1111
Savard ML and Gilchrist DM (1989) Ependymomas in two sisters and a maternal
male cousin with mosaicism with monosomy 22 in tumour. Pediatr Neurosci
15: 80–84
Sirotkin H, O’Donnell H, DasGupta R, Halford S, St. Jore B, Puech A, Parimoo S,
Morrow B, Skoultchi A, Weissman SM, Scambler P and Kucherlapati R (1997)
Identification of a new catenin gene family member (ARVCF) from the region
deleted in Velo-Cardio-Facial Syndrome. Genomics 41: 75–83
Slavc I, MacCollin MM, Dunn M, Jones S, Sutton L, Gusella JF and Biegel JA
(1995) Exon scanning for mutations of the NF2 gene in pediatric
ependymomas, rhabdoid tumors and meningiomas. Int J Cancer 64: 243–247
Speicher MR, Jauch A, Walt H, du Manoir S, Ried T, Jochum W, Sulser T and
Cremer T (1995) Correlation of microscopic phenotype with genotype in a
formalin-fixed, paraffin-embedded testicular germ cell tumor with universal
DNA amplification, comparative genomic hybridization, and interphase
cytogenetics. Am J Pathol 146: 1332–1340
Von Haken MS, White EC, Daneshvar-Shyesther L, Sih S, Choi E, Kalra R and
Cogen PH (1996) Molecular genetic analysis of chromosome arm 17p and
chromosome arm 22q sequences in sporadic pediatric ependymomas Genes
Chromosomes Cancer 17: 37–44
Weremowicz S, Kupsky WJ, Morton CC and Fletcher JA (1992) Cytogenetic
evidence for a chromosome 22 tumor suppressor gene in ependymoma. Cancer
Genet Cytogenet 61: 193–196